COMPARISON OF TOPICAL ANTIBIOTICS FOR TREATING MYCOBACTERIUM-FORTUITUM KERATITIS IN AN ANIMAL-MODEL

被引:35
作者
HELM, CJ
HOLLAND, GN
LIN, R
BERLIN, OGW
BRUCKNER, DA
机构
[1] UNIV CALIF LOS ANGELES, JULES STEIN EYE INST, DEPT OPHTHALMOL, CTR OCULAR INFLAMMATORY DIS, LOS ANGELES, CA 90024 USA
[2] UNIV CALIF LOS ANGELES, SCH MED, DEPT PATHOL, DIV CLIN MICROBIOL, LOS ANGELES, CA 90024 USA
关键词
D O I
10.1016/S0002-9394(14)73469-5
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
The efficacy of three topical antibiotic treatments for Mycobacterium fortuitum (strain ATCC-6841) keratitis were compared in rabbits. Rabbits were treated with ciprofloxacin (3 mg/ml) or clarithromycin (20 mg/ml) or a combination of amikacin (100 mg/ml) and vancomycin (50 mg/ml). All three treatments significantly reduced the number of organisms in treated eyes compared to untreated, control eyes (all P values <.001). No significant difference in treatment efficacy was found between the three treatment groups (all P values greater than or equal to.48), although ciprofloxacin (3 mg/ml) was more effective than clarithromycin (20 mg/ml) after excluding outliers (P =.01). All treatments stabilized or reduced the size of stromal infiltrates after four days of therapy, whereas infiltrates continued to enlarge in untreated eyes. These results suggest that topical clarithromycin, topical ciprofloxacin, and combined amikacin and vancomycin may all be clinically useful for treating M. fortuitum keratitis. Both clarithromycin and ciprofloxacin were better tolerated than combined amikacin and vancomycin. This study supports the further development of clarithromycin, a new macrolide antibiotic, as a topical drug for treatment of M. fortuitum keratitis.
引用
收藏
页码:700 / 707
页数:8
相关论文
共 35 条
[1]   THE NEW MACROLIDE ANTIBIOTICS - AZITHROMYCIN, CLARITHROMYCIN, DIRITHROMYCIN, AND ROXITHROMYCIN [J].
BAHAL, N ;
NAHATA, MC .
ANNALS OF PHARMACOTHERAPY, 1992, 26 (01) :46-55
[2]   COMPARATIVE INVITRO ACTIVITY OF THE NEW MACROLIDE A-56268 AGAINST MYCOBACTERIA [J].
BERLIN, OGW ;
YOUNG, LS ;
FLOYDREISING, SA ;
BRUCKNER, DA .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1987, 6 (04) :486-487
[3]   ACTIVITIES OF 4 MACROLIDES, INCLUDING CLARITHROMYCIN, AGAINST MYCOBACTERIUM-FORTUITUM, MYCOBACTERIUM-CHELONAE, AND M-CHELONAE-LIKE ORGANISMS [J].
BROWN, BA ;
WALLACE, RJ ;
ONYI, GO ;
DEROSAS, V ;
WALLACE, RJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (01) :180-184
[4]   NONTUBERCULOUS MYCOBACTERIAL KERATITIS - REPORT OF 2 CASES AND REVIEW OF THE LITERATURE [J].
BULLINGTON, RH ;
LANIER, JD ;
FONT, RL .
ARCHIVES OF OPHTHALMOLOGY, 1992, 110 (04) :519-524
[5]   INVITRO SUSCEPTIBILITY OF MYCOBACTERIA TO CIPROFLOXACIN [J].
COLLINS, CH ;
UTTLEY, AHC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 16 (05) :575-580
[6]   INVITRO SUSCEPTIBILITY OF MYCOBACTERIUM-FORTUITUM AND MYCOBACTERIUM-CHELONEI TO AMIKACIN [J].
DALOVISIO, JR ;
PANKEY, GA .
JOURNAL OF INFECTIOUS DISEASES, 1978, 137 (03) :318-321
[7]  
DIXON WJ, 1983, INTRO STATISTICAL AN, P328
[8]   MYCOBACTERIUM-FORTUITUM KERATITIS [J].
DUGEL, PU ;
HOLLAND, GN ;
BROWN, HH ;
PETTIT, TH ;
HOFBAUER, JD ;
SIMONS, KB ;
ULLMAN, H ;
BATH, PE ;
FOOS, RY .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1988, 105 (06) :661-669
[9]  
GARCIARODRIGUEZ JA, 1978, TUBERCLE, V59, P277, DOI 10.1016/0041-3879(78)90005-3
[10]   IDENTIFICATION OF MYCOBACTERIUM-FORTUITUM, MYCOBACTERIUM-ABSCESSUS, AND MYCOBACTERIUM-BORSTELENSE BY POLYACRYLAMIDE-GEL ELECTROPHORESIS OF THEIR CELL PROTEINS [J].
HAAS, H ;
MICHEL, J ;
SACKS, T .
INTERNATIONAL JOURNAL OF SYSTEMATIC BACTERIOLOGY, 1974, 24 (03) :366-369